Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

65.81 -1.33 (-1.97%)
Delayed Quote Updated: 10:31 AM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 69,332
Open 67.20
Bid (Size) 64.95 (100)
Ask (Size) 65.97 (100)
Prev. Close 67.14
Today's Range 64.92 - 67.40
52wk Range 32.21 - 170.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
From GeneDx
Via Business Wire
News headline image
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
From GeneDx
Via Business Wire

Performance

52-Week Range 61.5% below 52-week high
65.81
32.2152W Low 170.8752W High
1 Week 8.0% below 1-week high
62.491W Low 71.531W High

GeneDx Holdings Corp. - Class A Common Stock (WGS) traded between $32.21 and $170.87 over the past 52 weeks and last traded at $65.81, 61.5% below its 52-week high. Over the past week it ranged between $62.49 and $71.53.

Past 12 Months
+3.5%
-27.5%
+3.8%
-0.6%
-50.3%
-45.6%
1W +$2.20
1M -$24.98
3M +$2.43
6M -$0.42
YTD -$66.49
1Y -$55.20

WGS was -45.6% over the past year, -0.6% over six months, -50.3% year to date, +3.5% in the last week.

12 Months vs Market
WGS
-45.6%
DIA
+11.8%
SPY
+13.8%
QQQ
+16.4%
IWM
+12.6%

Over the past 12 months WGS returned -45.6% versus DIA (Dow) +11.8%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +16.4% and IWM (Russell 2000) +12.6%.

Volume & Liquidity 0.10× 3-mo avg
Today 69,332 3-mo avg 726.6K
1W
692.0K
1M
810.4K
3M
726.6K
6M
1.0M
YTD
918.5K
1Y
839.8K

WGS most recently traded 69,332 shares against a 3-month average daily volume of 726.6K.

More News

Read More
News headline image
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
From GeneDx
Via Business Wire
News headline image
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
From GeneDx
Via Business Wire
GeneDx Holdings (NASDAQ:WGS) Beats Q2 Revenue Estimates and Swings to Adjusted Profit ↗
Via Chartmill
News headline image
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
From GeneDx
Via Business Wire
News headline image
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
From GeneDx
Via Business Wire
News headline image
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
From GeneDx
Via Business Wire
News headline image
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
From GeneDx
Via Business Wire
News headline image
GeneDx (WGS) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
GeneDx to Participate in Upcoming Investor Conferences
From GeneDx
Via Business Wire
News headline image
GeneDx Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
GeneDx Reports Second Quarter 2026 Financial Results
From GeneDx
Via Business Wire
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Law
From Schall Law
Via GlobeNewswire
News headline image
GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. - WGS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
GENEDX HOLDINGS DEADLINE MONDAY AUGUST 3rd: Bragar Eagel & Squire, P.C. Urges GeneDx Holdings Corp. Investors to Contact the Firm Regarding Lead Plaintiff Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Via Newsfile
Topics Fraud Lawsuit
News headline image
GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS
From SkyMedia, LLC
Via GlobeNewswire
News headline image
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Via Newsfile
Topics Fraud Lawsuit
News headline image
WGS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines – WGS
From Pomerantz LLP
Via GlobeNewswire
News headline image
GENEDX HOLDINGS DEADLINE AUGUST 3rd: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Via Newsfile
Topics Fraud Lawsuit

Frequently Asked Questions

Is GeneDx Holdings Corp. - Class A Common Stock publicly traded?
Yes, GeneDx Holdings Corp. - Class A Common Stock is publicly traded.
What exchange does GeneDx Holdings Corp. - Class A Common Stock trade on?
GeneDx Holdings Corp. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeneDx Holdings Corp. - Class A Common Stock?
The ticker symbol for GeneDx Holdings Corp. - Class A Common Stock is WGS on the Nasdaq Stock Market
What is the current price of GeneDx Holdings Corp. - Class A Common Stock?
The current price of GeneDx Holdings Corp. - Class A Common Stock is 65.81
When was GeneDx Holdings Corp. - Class A Common Stock last traded?
The last trade of GeneDx Holdings Corp. - Class A Common Stock was at 10/23/26 10:31 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.